Drug Discovery
By
Can Roche’s $700M Genentech Facility Drive Its $50B US Investment Strategy and Transform Obesity Drug Manufacturing?
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Can Novartis and BioArctic’s $802M Alliance Unlock the Next Breakthrough in Neurodegenerative Drug Delivery?
Key Highlights Strategic Collaboration Targets Neurodegenerative DiseasesNovartis has entered into a research partnership with Sweden’s BioArctic, committing $30M…
Could Halda Therapeutics and VantAI’s $1B AI Alliance Redefine the Future of Cancer Drug Discovery?
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
How AbbVie Is Expanding Its Psychiatry Pipeline Through $1.2B Acquisition of Gilgamesh Pharmaceuticals’s Next-Gen Depression Drug?
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL Amyloidosis?
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
